1483O Results of a phase I/II combination regimen with ipilimumab (I), nivolumab (N) and trabectedin (T) as first line therapy for advanced leiomyosarcoma
Gordon, E., Tellez, W.A., Brigham, D.A., Valencia, C., Chawla, S.P., Chua-Alcala, V., Moradhkani, A.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article
1925P Results of SOC-2082 phase II study using metronomic gemcitabine, doxorubicin, and docetaxel plus nivolumab as second/third-line therapy for advanced leiomyosarcoma
Chawla, N.S., Omelchenko, N., Makrievski, S., De Melo, G. Leão, Brigham, D., Ahari, A., Chua Alcala, V.S., Moradhkani, A., Quon, D., Wong, S., Chawla, S.P., Gordon, E.M.
Published in Annals of oncology (01.10.2023)
Published in Annals of oncology (01.10.2023)
Get full text
Journal Article